New lupus drug APG-2575 enters human safety trials
NCT ID NCT06182969
First seen Jan 10, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study is testing a new drug called APG-2575 in 40 people with mild-to-moderate lupus. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital Shanghai Jiaotong University School of Medical
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.